Immunotherapy in Combination with Chemoradiation in Patients with Advanced Solid Tumors - CLOVER

Study identifier:D933BC00001

ClinicalTrials.gov identifier:NCT03509012

EudraCT identifier:2017-002242-77

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase I Multicenter Study of Immunotherapy in Combination with Chemoradiation in Patients with Advanced Solid Tumors (CLOVER)

Medical condition

Carcinoma, squamous cell of head and neck

Phase

Phase 1

Healthy volunteers

No

Study drug

Durvalumab, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, Cisplatin (dose level 1), Cisplatin (dose level 2)

Sex

All

Actual Enrollment

105

Study type

Interventional

Age

18 Years - 110 Years

Date

Study Start Date: 02 May 2018
Primary Completion Date: 31 Dec 2020
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria